TriNetX expands network: Pharma to ‘spin-up sites and recruit patients faster’

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/m1366)
(Image: iStock/m1366)

Related tags: Clinical trial, Medicine, Pharmaceutical industry

Weill Cornell Medicine has joined TriNetX’s global health research network, enabling it to collaborate with researchers and attract clinical trial opportunities.

Weill Cornell Medicine is an integrated academic healthcare delivery system, and as a TriNetX global health research network member, its patient population data is now available for query through TriNetX’s federated network.

The de-identified data includes patient demographics, diagnoses, procedures, labs, and medications, for a total population of more than two million.

Gadi Lachman, CEO of TriNetX, told us that as a network member, Weill Cornell has the ability to collaborate with researchers at more than 68 healthcare organizations. It will also be able to attract clinical trial opportunities from pharmaceutical companies and contract research organizations (CROs).  

With the addition of every new healthcare organization to the TriNetX network, comes the opportunity for pharmaceutical companies to operationalize clinical trials in that community, enabling the healthcare provider to present new therapies to its patients and allowing pharmaceutical companies to spin-up sites and recruit patients faster​,” said Lachman.

The TriNetX network includes healthcare organizations representing approximately 100m patients globally, as well as biopharmaceutical companies and CROs. Members are able to use the company’s cloud-based health research platform to analyze patient populations and perform “what-if​” analyses in real-time.

Additionally, Lachman said a huge benefit for TriNetX’s healthcare organizations is peer-to-peer collaboration. “TriNetX handles the mapping and curating of data so that hospitals do not have to expend IT resources normalizing their data to an external standard in order to support multi-site research​,” he explained.

Collaborations and growth

Earlier this month, TriNetX announced a partnership with Sanofi​, through which it will work to reduce clinical trial complexity and speed development timelines for the pharma company.

The goal of the partnership is “to simplify and to make better, earlier, and more informed decisions​,” said Vicky DiBiaso, global head of clinical operations strategy and collaboration within Sanofi’s R&D organization.

Late last year, TriNetX also completed a yearlong project to move its headquarters​ to Cambridge, MA.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more